Read more at MarketWatch.
Goldman says these companies with high labor costs should benefit as job market slows
Date: |
Topics
-
BBC News - Top stories
Sickness benefit claimants should look for work, says PM
The prime minister has said the public will have to make "trade-offs" if the country is to improve.9 hours ago -
Financial Times - World
Russia is weighing the costs and benefits of retaliation
Putin faces constraints in responding to possible expanded US and allied military support for Ukraine3 hours ago - Russia -
Yahoo News - World
Bank of France Chief Says Bond Markets Are Warning on Debt
6 hours ago -
Inc. - Business
Shopify Founder Tobi Lütke Says Every Leader Should Know This 1 Untranslatable German Word
Having a word for this common pitfall helps leaders watch out for and prevent it.5 hours ago -
CNBC - Business
Never ask these 3 questions on a first date, dating coaches say—including one you should 'avoid outright'
Most conversations are fair game, but there are a few questions that might sidetrack you from the goal of a first date: forming connection.15 hours ago -
The New York Times - Top stories
I’m a Chef. This Grain Should Be the Next Quinoa.
As climate change threatens the availability of food, we must diversify what’s on our plates.37 minutes ago -
Financial Times - World
The stock market can’t save social security
Arbitrage for the public good?8 hours ago
More from MarketWatch
-
MarketWatch - Business
Merrill Lynch and Harvest Volatility paying $9.3 million in fines for derivatives trades
Fines follow probe of Harvest’s Collateral Yield Enhancement Strategy (CYES).9 minutes ago -
MarketWatch - Business
No trust is set in stone. Even irrevocable trusts can have some wiggle room.
Media titan Rupert Murdoch is in court to test the boundaries of changing permanent estate plans.12 minutes ago -
MarketWatch - Business
New-home sales fall 4.7% in August
New-home sales fell in August, but still beat estimates.18 minutes ago -
MarketWatch - Business
Merck says trial of combination treatment for colon cancer failed to meet main goal
Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of ...26 minutes ago -
MarketWatch - Business
Chinese stocks extend gains after Beijing’s stimulus bazooka
Chinese stocks on Wednesday extended their rally triggered by Beijing’s stimulus bazooka, though optimism elsewhere in the region could not be sustained37 minutes ago - China